Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

This trial is studying whether adding probiotics (beneficial gut bacteria supplements) to the standard treatment — combined chemotherapy and radiation — plus maintenance immunotherapy with adebrelimab, improves outcomes for patients with limited-stage small cell lung cancer. **You may be eligible if...** - You are aged 18–80 - You have been confirmed to have small cell lung cancer, limited stage (confined to one side of the chest) - Your performance status is good (ECOG 0–1) - You have received no more than 2 rounds of prior chemotherapy or chemo-immunotherapy - Your expected survival is more than 3 months **You may NOT be eligible if...** - Your cancer progressed after 2 rounds of initial treatment - You have severe emphysema, significant COPD, or lung interstitial changes - Your resting blood oxygen is below 93% - You have had another cancer requiring chemotherapy in the past 3 years - You have previously received chest radiation Talk to your doctor to see if this trial is right for you.